GenSight Biologics Secures €3.7 Million in Funding to Advance Gene Therapy Development

"GenSight Biologics, a biopharmaceutical company focused on innovative gene therapies for neurodegenerative retinal diseases and central nervous system disorders, has raised nearly €3.7 million through a new funding round. This funding, obtained via the issuance of new shares and warrants, aims to secure cash flow and support the development of its advanced Phase III drug candidate, GS010/LUMEVOQ®. The company was advised by CMS Francis Lefebvre, which has previously assisted them in private placements."

**Press Release Summary** The law firm CMS Francis Lefebvre participated in the transaction by advising GenSight Biologics. GenSight Biologics, a biopharmaceutical company specializing in the development and commercialization of innovative gene therapies for neurodegenerative diseases of the retina and central nervous system disorders, successfully raised nearly €3.7 million through the issuance of new shares and warrants (either pre-financed or not). This fundraising aims to secure the company's cash needs and support the continued development of GS010/LUMEVOQ®, GenSight Biologics' most advanced phase III drug candidate. The team from CMS Francis Lefebvre included Bertrand Sénéchal, Partner, and associates Délany Chelliah and Pierre Maunand. CMS Francis Lefebvre had previously advised GenSight Biologics on two successive private placements in July 2025.

GenSight Biologics Secures €3.7 Million in Funding to Advance Gene Therapy Development

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads